Biofrontera Inc. (BFRI)
Market Cap | 4.32M |
Revenue (ttm) | 35.36M |
Net Income (ttm) | -12.84M |
Shares Out | 5.54M |
EPS (ttm) | -3.09 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 280,721 |
Open | 0.775 |
Previous Close | 0.760 |
Day's Range | 0.692 - 0.790 |
52-Week Range | 0.610 - 4.040 |
Beta | 0.51 |
Analysts | Strong Buy |
Price Target | 7.00 (+797.55%) |
Earnings Date | Nov 13, 2024 |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate seve... [Read more]
Financial Performance
In 2023, Biofrontera's revenue was $34.07 million, an increase of 18.82% compared to the previous year's $28.67 million. Losses were -$20.13 million, 3045.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BFRI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.
News
Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Andrew Barwicki - Investor Relations Hermann Luebbert - Chief Executive Officer, Cha...
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, ...
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic pro...
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that manageme...
Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI) Q2 2024 Earnings Conference Call August 15, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Fou...
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported...
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financ...
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
WOBURN, MA, June 24, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, is proud to announce the laun...
Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript
Biofrontera Inc. (NASDAQ:BFRI) Q1 2024 Earnings Conference Call May 16, 2024 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - Chief Executive Officer,...
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company special...
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will repor...
Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants
WOBURN, MA / ACCESSWIRE / May 3, 2024 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced th...
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announce...
Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets) Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBU...
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024 WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company spec...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will rep...
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer
Provides Corporate Update on Financing and Investor Relations Toronto, Ontario--(Newsfile Corp. - March 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased t...
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and rec...
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
Ameluz ® transfer price to Biofrontera AG reduced significantly Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1 WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofro...
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and re...
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
FDA has set a target action date of October 4, 2024 sNDA supported by two Phase 1 safety studies1 Aims at actinic keratosis (AK) field treatment with up to 3 tubes An estimated 13 million treatments g...